

WOCKHARDT BIO AG
Petitioner

v.

JAZZ PHARMACEUTICALS, INC.
Patent Owner

CASE: Unassigned
Patent 7,668,730

WOCKHARDT BIO AG'S EXHIBIT LIST

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

1002	issued Feb. 23, 2010)
1003	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Transcript and Slides (July 13, 2001)
1004	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information, Division of Neuropharmacological Drug Products Preliminary Clinical Safety Review of NDA 21-196 (July 13, 2001)
1005	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information, Briefing Booklet (July 13, 2001)
1006	FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information, Xyrem Video and Transcript
1007	Declaration of Dr. Robert J. Valcuk, Ph.D., R.Ph.
1008	<i>Curriculum Vitae</i> of Dr. Robert J. Valuck, Ph.D., R.Ph.
1009	Shulman, S., "The Broader Message of Accutane," <i>Am. J. of Public Health</i> , 79:1565-1568 (1989)
1010	Spurgeon, D., "Advent of Mail-Order Pharmacy Causes Concern Among Some Pharmacists," <i>Can. Med. Assoc. J.</i> , 152:1485-1486 (1995)
1011	Honigfeld, G., "Effects of the Clozapine National Registry System on Incidence of Deaths Related to Agranulocytosis," <i>Psychiatric Services</i> , 47:52-56 (1996)
1012	Burleson, K., "Review of computer applications in institutional pharmacy—1975-1981," <i>Am. J. Hosp. Pharm.</i> , 39:53-70 (1982)
1013	Zeldis, J., <i>et al.</i> , "S.T.E.P.S. TM : A comprehensive Program for Controlling and Monitoring Access to Thalidomide," <i>Clin. Therapeutics</i> , 21:319-330 (1999)
1014	"Managing the Risks from Medical Product Use: Creating a Risk Management Framework," Report to the FDA Commissioner
1015	66 Fed. Reg. 24391

1017	Advisory Committee's Meeting Documents by Center, available at http://www.fda.gov/ohrms/dockets/ac/01docsbc.htm
1018	Internet Archive Wayback Machine, Center for Drug Evaluation and Research 2001 Meeting Documents, available at https://web.archive.org/web/20010617210030/http://www.fda.gov/ohrms/dockets/ac/cder01.htm (dated June 17, 2001)
1019	Internet Archive Wayback Machine, FDA Peripheral & Central Nervous System Drugs Advisory Committee, Briefing Information for Xyrem NDA 21-196, available at https://web.archive.org/web/20010701233052/http://www.fda.gov/ohrms/dockets/ac/01/briefing/3754b1.htm (dated July 1, 2001)
1020	Internet Archive Wayback Machine, Center for Drug Evaluation and Research 2001 Meeting Documents, available at https://web.archive.org/web/20011004081740/http://www.fda.gov/ohrms/dockets/ac/cder01.htm (dated Oct. 4, 2001)
1021	Orange Book Entries for Xyrem®, available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=021196&TABLE1=OB_Rx ; and http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021196&Product_No=001&table1=OB_Rx
1022	Rome, E., "It's a rave new world: Rave culture and illicit drug use in the young," <i>Cleveland Clinic J. of Med.</i> , 68:541-550 (2001)
1023	FDA Center for Drug Evaluation and Research, NDA 21-196, Approved Labeling, available at http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-196_Xyrem_prntlbl_P1.pdf
1024	INTENTIONALLY LEFT BLANK
1025	INTENTIONALLY LEFT BLANK
1026	INTENTIONALLY LEFT BLANK

	20&%20Central%20Nervous 1/
1028	Affidavit from the Internet Archive Wayback Machine
1029	Mitchell, A., "A Pregnancy-Prevention Program in Women of Childbearing Age Receiving Isotretinoin," <i>The New England Journal of Medicine</i> , 333:101-106 (1995)
1030	INTENTIONALLY LEFT BLANK
1031	INTENTIONALLY LEFT BLANK
1032	Scrima, L., <i>et al.</i> , "Efficacy of Gamma-Hydroxybutyrate versus Placebo in Treating Narcolepsy-Cataplexy: Double-Blind Subjective Measures," <i>Biol. Psychiatry</i> , 26:331-343 (1989).

Date: August 27, 2015
100 High Street, Suite 2400
Boston, MA 02110
(857) 488-4200

Respectfully submitted,
DUANE MORRIS LLP

Laura A. Vogel
Registration No. 55,702
Attorney for Petitioner

following parties via electronic mail:
Schwegman Lundberg &
Woessner/Jazz Pharmaceutical

P.O. Box 2938
Minneapolis, MN 55402
*Patent owner's correspondence
address of record for U.S. Patent No.
7,668,730*


Date: August 27, 2015
100 High Street, Suite 2400
Boston, MA 02110
(857) 488-4200

F. Dominic Cerrito
Eric C. Stops
Gabriel P. Brier

QUINN EMANUEL URQUHART &
SULLIVAN LLP
51 Madison Avenue
22nd Floor
New York, NY 10010

*Additional address known to
Petitioner as likely to effect service*

Respectfully submitted,
DUANE MORRIS LLP



Laura A. Vogel
Registration No. 55,702
Attorney for Petitioner